Search
Chloroxine
go.drugbank.com/drugs/DB01243ApprovedWithdrawnChloroxine is a compound used in some shampoos for the treatment of dandruff and seborrheic dermatitis of the scalp.
Pegcetacoplan
go.drugbank.com/drugs/DB16694ApprovedInvestigational[A235000] Pegcetacoplan for subcutaneous use was granted FDA approval on 14 May 2021. … Pegcetacoplan is a complement inhibitor indicated in the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Enoxaparin
go.drugbank.com/drugs/DB01225ApprovedInvestigationalEnoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. … Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies.
Products: LOVENOX 10.000 IE (100 mg)/1 ml Injektionslösung in einer Fertigspritze, LOVENOX 15.000 IE (150 mg)/1 ml Injektionslösung in einer FertigspritzeIsosorbide dinitrate
go.drugbank.com/drugs/DB00883ApprovedInvestigationalA vasodilator used in the treatment of angina pectoris. Its actions are similar to nitroglycerin but with a slower onset of action.
Categories: Vasodilators Used in Cardiac DiseasesAltretamine
go.drugbank.com/drugs/DB00488ApprovedWithdrawnAn alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects.
Etilefrine
go.drugbank.com/drugs/DB08985ApprovedWithdrawnEtilefrine is an adrenergic agonist that appears to interact with beta-1 and some alpha-adrenergic receptors. It has been used as a vasoconstrictor agent.
Categories: Compounds used in a research, industrial, or household settingMazindol
go.drugbank.com/drugs/DB00579ApprovedMazindol is only approved in the United States for the treatment of Duchenne muscular dystrophy, and is not marketed or available in the United States for use in the treatment of obesity.
Nilutamide
go.drugbank.com/drugs/DB00665ApprovedInvestigationalNilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer.
Zileuton
go.drugbank.com/drugs/DB00744ApprovedWithdrawnBoth the R(+) and S(-) enantiomers are pharmacologically active as 5-lipoxygenase inhibitors in in vitro systems. The immediate release tablet of Zileuton has been withdrawn from the US market. … These effects contribute to inflammation, edema, mucus secretion, and bronchoconstriction in the airways of asthmatic patients.
Synonyms: N-(1-Benzo(b)thien-2-ylethyl)-N-hydroxyurea, N-[1-(benzo[b]thiophen-2-yl)ethyl]-N-hydroxyureaRoflumilast
go.drugbank.com/drugs/DB01656ApprovedInvestigationalThe cream formulation was first approved by the FDA in July 2022 [L42580] and by Health Canada in April 2023. … [L46546] It was first approved by the EMA in July 2010, and by the FDA in January 2018.[L37564] Roflumilast topical cream is indicated to treat plaque psoriasis.